As of 1:30 PM on the 16th, Celltrion is trading at 298,000 KRW, up 0.68% from the previous day. The trading volume is 295,161 shares, which is 74.12% of the previous day's volume. Celltrion is known as a manufacturer of protein and biopharmaceutical products.


On September 11, Shin Jae-hoon, a researcher at Hanwha Investment & Securities, made an impressive statement: "Celltrion is already leading the biosimilar market and will continue to lead the market based on its brand value." The company's investment points are R&D and performance. R&D is progressing without any setbacks, and the possibility of performance improvement was already confirmed in the second quarter results. The COVID-19 treatment is also expected to have a positive impact on profitability. Accordingly, the opinion of the top preferred stock in the sector is maintained." He set Celltrion's target price at 450,000 KRW.


Over the past five days, individual investors have net purchased 417,898 shares of Celltrion, while foreigners and institutions have net sold 261,774 shares and 258,411 shares, respectively.



※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing